⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
AICAR and Pharmacologic AMPK Agonists
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-29 — Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies: cross-connection with ampk-activators: Both pages concern pharmacological AMPK activation; the cross-species invertebrate lifespan result generalizes the mechanistic case that AICAR and related agonists target. (novelty: 3)
- 2026-09-15 — Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK.: Mouse study (animal-model): AICAR reversed liver aging phenotype and restored regeneration in hepassocin-knockout aged mice, supporting AMPK activation as the downstream effector rescuing the age-related hepatokine deficit. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK.
15-sep-2026
novelty 3
per-area 3
strengthens